Tenosynovial giant cell tumor, diffuse type
MONDO:0024686A locally aggressive, diffusely infiltrating tumor, arising in the tendon sheath. It is composed of synovial-like mononuclear cells, hemosiderin-laden macrophages, foam cells, and inflammatory cells. Multinucleated osteoclast-like giant cells are usually present, although in a minority of cases they may be absent or rare. It predominantly affects young adults. Symptoms include joint swelling, pain, and joint effusion.
Also known as: TGCT, TSGCT, Tenosynovial Giant Cell Tumor, diffuse giant cell neoplasm of Tenosynovium, diffuse giant cell neoplasm of tendon sheath, diffuse giant cell neoplasm of the Tenosynovium, diffuse giant cell tumor of Tenosynovium, diffuse giant cell tumor of tendon sheath
1468 clinical trials for this condition and its sub-types, 9 tagged with Tenosynovial giant cell tumor, diffuse type itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug hope for rare joint tumor patients who Can't have surgery
Disease control CompletedThis study tested a drug called pexidartinib (TURALIO) in 9 Japanese adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and limits movement. The goal was to see if the drug is safe and can shrink tumors in people whose tu…
Phase 2 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Leukemia drug shows promise against rare joint tumors
Disease control CompletedThis study tested nilotinib, a drug originally used for leukemia, in 17 patients with relapsed or metastatic pigmented villonodular synovitis (PVNS) or related giant cell tumors. The goal was to see if the drug could stop tumor growth or improve symptoms. Results focused on how l…
Phase 2 • Sponsor: Andrew J. Wagner, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC